R

Research Institute of Dallas | Dallas, TX

Research site

(Unclaimed)

Location

10260 N Central Expressway, Suite 100 N, Dallas, Texas, United States of America

Site insights

Top conditions

Top treatments

Empagliflozin

Bococizumab

Dapagliflozin

Tirzepatide

Teplizumab

Metformin

Octreotide

BMS-512148

Paltusotine

LY3298176

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

3 of 46 total trials

A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes (ONWARDS 11)

This study compares insulin icodec, an insulin taken once a week to insulin glargine, an insulin taken once a day. The study medicine will be investi...

Not yet enrolling

Diabetes Mellitus, Type 1

Drug: Insulin glargine

Drug: Insulin icodec

A Study to Assess the Efficacy, Safety, and Pharmacokinetics of Debio 4326 in Pediatric Participants With Central Precocious Puberty (LIBELULA™ Clinical Trial)

The primary objective of this study is to evaluate the efficacy of Debio 4326 in suppressing serum luteinizing hormone (LH) to prepubertal levels 52...

Enrolling

Central Precocious Puberty

Drug: Debio 4326

Open-Label Extension Study of DCCR in Patients With Prader-Willi Syndrome

The purpose of this is study is to evaluate the long-term safety of DCCR (diazoxide choline) extended-release tablets) in patients with Prader-Willi...

Active, not recruiting

Prader-Willi Syndrome

Drug: DCCR